Vazoaktivni intestinalni peptid
| edit |
| Vazoaktivni intestinalni peptid | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifikatori | |||||||||||
| Simboli | VIP; MGC13587; PHM27 | ||||||||||
| Vanjski ID | OMIM: 192320 MGI: 98933 HomoloGene: 2539 GeneCards: VIP Gene | ||||||||||
| |||||||||||
| Pregled RNK izražavanja | |||||||||||
 | |||||||||||
| podaci | |||||||||||
| Ortolozi | |||||||||||
| Vrsta | Čovek | Miš | |||||||||
| Entrez | 7432 | 22353 | |||||||||
| Ensembl | ENSG00000146469 | ENSMUSG00000019772 | |||||||||
| UniProt | P01282 | P32648 | |||||||||
| RefSeq (mRNA) | NM_003381 | NM_011702 | |||||||||
| RefSeq (protein) | NP_003372 | NP_035832 | |||||||||
| Lokacija (UCSC) | Chr 6: 153.11 - 153.12 Mb | Chr 10: 4.7 - 4.71 Mb | |||||||||
| PubMed pretraga | [1] | [2] | |||||||||
Vazoaktivni intestinalni peptid (VIP) je peptidni hormon koji sadrži 28 aminokiselinskih ostataka. On se proizvodi u mnogim delovima ljudskog tela: crevima, pankreasu i suprahiazmatičnom jezgru hipotalamusa u mozgu.[1][2] Kod ljudi je vazoaktivni intestinalni peptid kodiran VIP genom.[3]
Vreme poluraspada VIP proteina (T1/2) u krvi je oko dva minuta.
VIP ima uticaja na nekoliko različitih delova tela:
- U sistemu organa za varenje, VIP izgleda da indukuje relaksaciju glatkih mišića, stimuliše izlučivanje vode u pankreasni sok i žuč, i izaziva inhibiciju izlučivanja gastrične kiseline i apsorpciju iz creva lumena.[4] Njegova uloga u crevima je da znatno stimuliše izlučivanje vode i elektrolita,[5] kao i stimulacija kontrakcija crevnih glatkih mišića, dilatacija perifernih krvnih žila, stimulacija pankresne sekrecije bikarbonata, i inhibicija gastrin-stimulisane sekrecije gastrične kiseline. Ovi efekti se dopunjavaju u povećanju motilnosti.[6]
- On takođe uzima učešće u stimulaciji sekrecije pepsinogena.[7]
- ↑ Fahrenkrug J, Emson PC (September 1982). „Vasoactive intestinal polypeptide: functional aspects”. Br. Med. Bull. 38 (3): 265–70. PMID 6129023.
- ↑ Said SI (April 1986). „Vasoactive intestinal peptide”. J. Endocrinol. Invest. 9 (2): 191–200. PMID 2872248.
- ↑ Linder S, Barkhem T, Norberg A, Persson H, Schalling M, Hökfelt T, Magnusson G (January 1987). „Structure and expression of the gene encoding the vasoactive intestinal peptide precursor”. Proc. Natl. Acad. Sci. U.S.A. 84 (2): 605–9. DOI:10.1073/pnas.84.2.605. PMC 304259. PMID 3025882.
- ↑ Bowen R (24. 1. 1999.). „Vasoactive Intestinal Peptide”. Pathophysiology of the Endocrine System: Gastrointestinal Hormones. Colorado State University. Arhivirano iz originala na datum 2012-02-04. Pristupljeno 6. 2. 2009.
- ↑ „Vasoactive intestinal polypeptide”. GPnotebook. Pristupljeno 6. 2. 2009.
- ↑ Bergman RA, Afifi AK, Heidger PM. „Plate 6.111 Vasoactive Intestinal Polypeptide (VIP)”. Atlas of Microscopic Anatomy: Section 6 - Nervous Tissue. www.anatomyatlases.org. Pristupljeno 6. 2. 2009.
- ↑ Sanders MJ, Amirian DA, Ayalon A, Soll AH (November 1983). „Regulation of pepsinogen release from canine chief cells in primary monolayer culture”. Am. J. Physiol. 245 (5 Pt 1): G641–6. PMID 6195927.[mrtav link]
- Fahrenkrug J (2002). „Gut/brain peptides in the genital tract: VIP and PACAP”. Scand. J. Clin. Lab. Invest. Suppl. 234: 35–9. PMID 11713978.
- Delgado M, Pozo D, Ganea D (2004). „The significance of vasoactive intestinal peptide in immunomodulation”. Pharmacol. Rev. 56 (2): 249–90. DOI:10.1124/pr.56.2.7. PMID 15169929.
- Conconi MT, Spinazzi R, Nussdorfer GG (2006). „Endogenous ligands of PACAP/VIP receptors in the autocrine-paracrine regulation of the adrenal gland”. Int. Rev. Cytol. 249: 1–51. DOI:10.1016/S0074-7696(06)49001-X. PMID 16697281.
- Hill JM (2007). „Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential”. Curr. Pharm. Des. 13 (11): 1079–89. DOI:10.2174/138161207780618975. PMID 17430171.
- Gonzalez-Rey E, Varela N, Chorny A, Delgado M (2007). „Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator”. Curr. Pharm. Des. 13 (11): 1113–39. DOI:10.2174/138161207780618966. PMID 17430175.
- „Quaternary structure of rabbit skeletal muscle glycogen synthetase” [Quaternary structure of rabbit skeletal muscle glycogen synthetase]. Doklady Akademii Nauk SSSR 222 (4): 997–1000. 1975. PMID 807467.
- Kitamura K, Kangawa K, Kawamoto M, et al. (1992). „Isolation and characterization of peptides which act on rat platelets, from a pheochromocytoma”. Biochem. Biophys. Res. Commun. 185 (1): 134–41. DOI:10.1016/S0006-291X(05)80966-0. PMID 1318039.
- Glowa JR, Panlilio LV, Brenneman DE, et al. (1992). „Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist”. Brain Res. 570 (1-2): 49–53. DOI:10.1016/0006-8993(92)90562-N. PMID 1617429.
- Theriault Y, Boulanger Y, St-Pierre S (1991). „Structural determination of the vasoactive intestinal peptide by two-dimensional H-NMR spectroscopy”. Biopolymers 31 (4): 459–64. DOI:10.1002/bip.360310411. PMID 1863695.
- Gozes I, Giladi E, Shani Y (1987). „Vasoactive intestinal peptide gene: putative mechanism of information storage at the RNA level”. J. Neurochem. 48 (4): 1136–41. DOI:10.1111/j.1471-4159.1987.tb05638.x. PMID 2434617.
- Yamagami T, Ohsawa K, Nishizawa M, et al. (1988). „Complete nucleotide sequence of human vasoactive intestinal peptide/PHM-27 gene and its inducible promoter”. Ann. N. Y. Acad. Sci. 527: 87–102. DOI:10.1111/j.1749-6632.1988.tb26975.x. PMID 2839091.
- Bodner M, Fridkin M, Gozes I (1985). „Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome”. Proc. Natl. Acad. Sci. U.S.A. 82 (11): 3548–51. DOI:10.1073/pnas.82.11.3548. PMC 397822. PMID 2987932.
- DeLamarter JF, Buell GN, Kawashima E, et al. (1985). „Vasoactive intestinal peptide: expression of the prohormone in bacterial cells”. Peptides 6 Suppl 1: 95–102. DOI:10.1016/0196-9781(85)90016-6. PMID 2995945.
- Linder S, Barkhem T, Norberg A, et al. (1987). „Structure and expression of the gene encoding the vasoactive intestinal peptide precursor”. Proc. Natl. Acad. Sci. U.S.A. 84 (2): 605–9. DOI:10.1073/pnas.84.2.605. PMC 304259. PMID 3025882.
- Gotoh E, Yamagami T, Yamamoto H, Okamoto H (1989). „Chromosomal assignment of human VIP/PHM-27 gene to 6q26----q27 region by spot blot hybridization and in situ hybridization”. Biochem. Int. 17 (3): 555–62. PMID 3202886.
- Yiangou Y, Di Marzo V, Spokes RA, et al. (1987). „Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide”. J. Biol. Chem. 262 (29): 14010–3. PMID 3654650.
- Gozes I, Bodner M, Shani Y, Fridkin M (1986). „Structure and expression of the vasoactive intestinal peptide (VIP) gene in a human tumor”. Peptides 7 Suppl 1: 1–6. DOI:10.1016/0196-9781(86)90156-7. PMID 3748844.
- Tsukada T, Horovitch SJ, Montminy MR, et al. (1985). „Structure of the human vasoactive intestinal polypeptide gene”. DNA 4 (4): 293–300. PMID 3899557.
- Heinz-Erian P, Dey RD, Flux M, Said SI (1985). „Deficient vasoactive intestinal peptide innervation in the sweat glands of cystic fibrosis patients”. Science 229 (4720): 1407–8. DOI:10.1126/science.4035357. PMID 4035357.
- Bloom SR, Christofides ND, Delamarter J, et al. (1984). „Diarrhoea in vipoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene”. Lancet 2 (8360): 1163–5. PMID 6139527.
